BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nuevolution Announces Research and Development Collaboration with Merck & Co., Inc. (MRK)


6/18/2008 6:58:03 AM

COPENHAGEN, June 18 /PRNewswire/ -- Nuevolution A/S today announced that it has entered into a drug discovery collaboration with Merck & Co. Inc.

Nuevolution will apply its proprietary Chemetics® drug discovery technology to identify novel small molecule leads against several drug targets of interest to Merck. The Chemetics® platform uses innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale.

Nuevolution will screen multiple multi-million member diverse fragment based screening libraries for hit identification. Through the design, synthesis and screening of target focused Chemetics® follow-up libraries, the parties will also work together to perform hit-to-lead optimization.

Under the terms of the agreement, Merck will provide Nuevolution with an upfront payment, research funding, and milestone payments as candidate molecules progress through preclinical and clinical development and onto the market. In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products. Further financial details were not disclosed.

"We are delighted that a company of Merck's stature has chosen to enter into collaboration with Nuevolution to access our fragment-based Chemetics® platform, which we believe has the potential to transform small molecule lead discovery." said Alex Gouliaev, CEO of Nuevolution A/S, and continued: "Working with Merck's world class team of scientists is an opportunity to further strengthen our approach and we look forward to an exciting and fruitful outcome of our collaboration."

About Nuevolution

Nuevolution is a leading drug discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies.

Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics® to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics® by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.

Nuevolution is a privately owned company and has raised EUR 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Venture and Novo A/S.

For more information about Nuevolution A/S, please visit the company's website http://www.nuevolution.com

Source: Nuevolution A/S

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES